Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SLS - SELLAS Life Sciences Group Inc


IEX Last Trade
1.29
-0.010   -0.775%

Share volume: 535,683
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.30
-0.01
-0.77%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
19%
Profitability 18%
Dept financing 15%
Liquidity 44%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
-2.27%
1 Month
3.20%
3 Months
-7.86%
6 Months
27.72%
1 Year
-11.03%
2 Year
-57.14%
Key data
Stock price
$1.29
P/E Ratio 
-2.01
DAY RANGE
N/A - N/A
EPS 
-$2.13
52 WEEK RANGE
$0.50 - $1.90
52 WEEK CHANGE
-$0.14
MARKET CAP 
82.989 M
YIELD 
N/A
SHARES OUTSTANDING 
64.332 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.56
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$368,468
AVERAGE 30 VOLUME 
$555,723
Company detail
CEO:
Region: US
Website:
Employees: 18
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.

Recent news